SAGE-217 + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Depression, Postpartum

Conditions

Depression, Postpartum

Trial Timeline

Jun 8, 2020 → Apr 12, 2022

NCT ID

NCT04442503

About SAGE-217 + Placebo

SAGE-217 + Placebo is a phase 3 stage product being developed by Biogen for Depression, Postpartum. The current trial status is completed. This product is registered under clinical trial identifier NCT04442503. Target conditions include Depression, Postpartum.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04442503	Phase 3	Completed	Jun 8, 2020	Apr 12, 2022	Depression, Postpartum
NCT04442490	Phase 3	Completed	May 12, 2020	Apr 21, 2021	Depressive Disorder, Major
NCT04007367	Phase 3	Terminated	Aug 6, 2019	Jan 6, 2020	Major Depressive Disorder
NCT03771664	Phase 3	Terminated	Feb 4, 2019	Jan 17, 2020	Major Depressive Disorder
NCT03672175	Phase 3	Completed	Nov 19, 2018	Mar 17, 2020	Major Depressive Disorder
NCT03692910	Phase 2	Completed	Aug 23, 2018	May 21, 2019	Bipolar Disorder I
NCT03000530	Phase 2	Completed	Dec 7, 2016	Nov 8, 2017	Major Depression

Competing Products

20 competing products in Depression, Postpartum

See all competitors

Product	Company	Stage	Hype Score
Olanzapine and Fluoxetine combination (OFC) + Fluoxetine	Eli Lilly	Phase 3	77
Duloxetine	Eli Lilly	Approved	85
FK949E	Astellas Pharma	Phase 3	77
Quetiapine	Astellas Pharma	Pre-clinical	23
duloxetine + escitalopram + placebo	Eli Lilly	Phase 3	77
duloxetine	Eli Lilly	Approved	85
Duloxetine Hydrochloride	Eli Lilly	Phase 3	77
Duloxetine	Eli Lilly	Approved	85
Duloxetine	Eli Lilly	Approved	85
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)	Eli Lilly	Approved	85
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine	Eli Lilly	Approved	85
duloxetine + fluoxetine + citalopram + paroxetine + sertraline	Eli Lilly	Approved	85
Olanzapine + Placebo	Eli Lilly	Phase 3	77
Olanzapine + Fluoxetine + Placebo	Eli Lilly	Phase 3	77
duloxetine + duloxetine	Eli Lilly	Pre-clinical	23
olanzapine + ziprasidone	Eli Lilly	Approved	85
Olanzapine Fluoxetine Combination (OFC) + Placebo	Eli Lilly	Approved	85
Drug treatment with Cymbalta	Eli Lilly	Approved	85
Duloxetine	Eli Lilly	Approved	85

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved

Dimethyl fumarateApproved

[18F]Florbetapir PET imagingApproved

dimethyl fumarateApproved

ibritumomab tiuxetan (Zevalin®)Approved